scholarly journals Association Between Angiotensin II Receptor Blockers and the Risk of Lung Cancer Among Patients With Hypertension From the Korean National Health Insurance Service-National Health Screening Cohort

2020 ◽  
Vol 53 (6) ◽  
pp. 476-486
Author(s):  
Sungji Moon ◽  
Hae-Young Lee ◽  
Jieun Jang ◽  
Sue K. Park
Keyword(s):  
Lung Cancer ◽  
Health Insurance ◽  
Angiotensin Ii ◽  
National Health Insurance ◽  
National Health ◽  
Health Screening ◽  
Angiotensin Ii Receptor Blockers ◽  
Angiotensin Ii Receptor ◽  
Receptor Blockers ◽  
Korean National Health Insurance

scholarly journals Evaluation of the relationship between previous statin use and thyroid cancer using Korean National Health Insurance Service-Health Screening Cohort data

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
So Young Kim ◽  
Young Shin Song ◽  
Jee Hye Wee ◽  
Chanyang Min ◽  
Dae Myoung Yoo ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Health Insurance ◽  
National Health Insurance ◽  
National Health ◽  
Conditional Logistic Regression ◽  
Health Screening ◽  
Cancer Group ◽  
Korean National Health Insurance ◽  
Adjusted Model ◽  
Statin Use

AbstractThe association of thyroid cancer with statin use is controversial. This study aimed to investigate the association of previous statin use with thyroid cancer in the ≥ 40-year-old population in the Korean National Health Insurance Service-Health Screening Cohort. The 5501 patients in the thyroid cancer group were matched with the 22,004 patients in the non-thyroid cancer group for age, sex, income, and region of residence. Previous statin use during the 2 years before the diagnosis of thyroid cancer was examined. The odds ratios (ORs) with 95% confidence intervals (CIs) of previous statin use for thyroid cancer were estimated using conditional logistic regression analyses. Additionally, subgroup analyses were conducted. The thyroid cancer group showed more days of previous statin use than the non-thyroid cancer group (72.3, standard deviation [SD] = 181.2 days vs. 64.3, SD = 174.4 days, P = 0.003). Although the odds of previous statin use for thyroid cancer were high in the crude model (OR = 1.10, 95% CI 1.04–1.17, P = 0.002), they were low in the fully adjusted model (OR = 0.89, 95% CI 0.82–0.95, P = 0.001). According to age and sex subgroups, the younger (< 60 years old) male group showed lower odds for thyroid cancer according to previous statin use (adjusted OR = 0.70, 95% CI 0.55–0.88, P = 0.003), but this finding was not observed in other subgroups of older men or in any groups of women. Thyroid cancer was negatively associated with statin use in the previous 2 years in the adjusted model.

Metabolic Syndrome and Risk of Lung Cancer: An Analysis of Korean National Health Insurance Corporation Database

2020 ◽  
Vol 105 (11) ◽  
Author(s):  
Sooim Sin ◽  
Chang-Hoon Lee ◽  
Sun Mi Choi ◽  
Kyung-Do Han ◽  
Jinwoo Lee
Keyword(s):  
Lung Cancer ◽  
Metabolic Syndrome ◽  
Health Insurance ◽  
National Health Insurance ◽  
National Health ◽  
Screening Program ◽  
Increased Risk ◽  
Korean National Health Insurance ◽  
The Impact ◽  
Metabolic Syndrome Components

Abstract Introduction Metabolic syndrome is known to increase the risk of several cancers. However, the association between lung cancer and metabolic syndrome remains unclear. Thus, we investigated the impact of metabolic syndrome on the incidence of lung cancer. Methods This study enrolled participants in a health screening program provided by the Korean National Health Insurance Service between January 2009 and December 2012. The incidence of lung cancer was observed until December 2016. We analyzed the risk of lung cancer according to the presence of metabolic syndrome, metabolic syndrome components, and number of metabolic syndrome components. Results During the study, 45 635 new cases of lung cancer were recorded among 9 586 753 participants. The presence of metabolic syndrome and all its components was positively associated with the risk of lung cancer in men after multivariate adjustment (hazard ratio [HR] of metabolic syndrome 1.15; 95% confidence interval [CI], 1.12-1.18). The risk of lung cancer increased with the number of components present. The effect of metabolic syndrome on the increasing risk of lung cancer is may be higher in underweight male ever-smokers than in other participants. Conclusion Metabolic syndrome was associated with an increased risk of lung cancer in men. Moreover, the higher the number of metabolic syndrome components, the higher the risk of lung cancer.

scholarly journals Hearing impairment increases economic inequality

2021 ◽  
Author(s):  
So Young Kim ◽  
Chanyang Min ◽  
Dae Myoung Yoo, ◽  
Jiwon Chang ◽  
Hyo-Jeong Lee ◽  
...  
Keyword(s):  
Health Insurance ◽  
Hearing Impairment ◽  
National Health Insurance ◽  
National Health ◽  
Economic Inequality ◽  
Income Level ◽  
Health Screening ◽  
Hearing Impaired ◽  
Cohort Data ◽  
Korean National Health Insurance

Objective. We evaluated the change in income level in a hearing-impaired population. Methods. The study subjects were selected from the Korean National Health Insurance Service-Health Screening Cohort data from 2002&#8211;2015 of Koreans

The Impact of Angiotensin-II Receptor Blockers on Cardiovascular Events in Hypertensive Patients – Evidence from Real-life Databases

2010 ◽  
Vol 6 (3) ◽  
pp. 33
Author(s):  
Robert J Petrella ◽  
Keyword(s):  
Angiotensin Ii ◽  
Antihypertensive Drugs ◽  
Real Life ◽  
Angiotensin Ii Receptor Blockers ◽  
Angiotensin Ii Receptor ◽  
Real World Setting ◽  
Actual Experience ◽  
Receptor Blockers ◽  
Randomised Controlled ◽  
The Impact

It is widely recognised that hypertension is a major risk factor for the development of future cardiovascular (CV) events, which in turn are a major cause of morbidity and mortality. Blood pressure (BP) control with antihypertensive drugs has been shown to reduce the risk of CV events. Angiotensin-II receptor blockers (ARBs) are one such class of antihypertensive drugs and randomised controlled trials (RCTs) have shown ARB-based therapies to have effective BP-lowering properties. However, data obtained under these tightly controlled settings do not necessarily reflect actual experience in clinical practice. Real-life databases may offer alternative information that reflects an uncontrolled real-world setting and complements and expands on the findings of clinical trials. Recent analyses of practice-based real-life databases have shown ARB-based therapies to be associated with better persistence and adherence rates and with superior BP control than non-ARB-based therapies. Analyses of real-life databases also suggest that ARB-based therapies may be associated with a lower risk of CV events than other antihypertensive-drug-based therapies.

Sign in / Sign up

Export Citation Format

Share Document